Kit Simpson to Coronary Disease
This is a "connection" page, showing publications Kit Simpson has written about Coronary Disease.
Connection Strength
0.431
-
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig. 2007; 27(1):67-74.
Score: 0.241
-
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009 Feb; 26(2):185-93.
Score: 0.070
-
Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Investig. 2007; 27(7):443-52.
Score: 0.060
-
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007; 27(12):807-17.
Score: 0.060